Nancy joined Illinois Ventures as CEO and Managing Director in 2013. Under her leadership, Illinois Ventures has invested in over 30 life science and technology ventures including Sfunga Therapeutics, Cystetic medicines, Actuate, Photonicare, Keywise AI, Psyonic, and Revolution Medicines (RVMD) which entered the public market in 2020.

Nancy spent her early career in startup formation and technology commercialization with a focus on business development and deal generation. She is a graduate of Northwestern University where she earned an MBA from the Kellogg School of Management, as well as a MS in Biotechnology. She earned her BA from Loyola University.